Changes in Beneficial Ownership · 4
Orchestra BioMed Holdings, Inc.
OBIONASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
tm2626947-1_4seq1.xml
Filing details
- Report period
- 2026-10-01
- Issuer
- Orchestra BioMed Holdings, Inc.
- Issuer CIK
- 0001814114
- Trading symbol
- OBIO
- Rule 10b5-1 indication
- Checked
Reporting owner 1
- Name
- Sherman Darren
- Reporting owner CIK
- 0001723524
- Relationship
- Director · Officer
- Officer title
- See Remarks
- Address
- C/O ORCHESTRA BIOMED HOLDINGS, INC., 150 UNION SQUARE DRIVE, NEW HOPE, PA, 18938
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.0001 per share ("Common Stock") | 2026-10-01 | S · Form 4[F1] | 15,000 | D | 6.36[F2] | 1,119,402 | D |
Table key
- S · Form 4
- Sale on the market or privately
- D
- Direct
Non-derivative holdings
| Security | Amount owned | Ownership | Nature of ownership |
|---|---|---|---|
| Common Stock | 2,000[F3] | I | By son |
Table key
- I
- Indirect
Footnotes
- F1
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 18, 2025.↩ 1
- F2
- The price reported is a weighted average price. These shares were disposed in multiple transactions at prices ranging from $6.20 to $6.48. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares disposed at each separate price within the range set forth in this footnote.↩ 1
- F3
- The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.↩ 1
Remarks
President and Chief Operating Officer
Signature 1
- Signed
- /s/ Andrew Taylor, Attorney-in-Fact
- Date
- 2026-10-02
Company context
Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. The Company’s two flagship product candidates, Atrioventricular Interval Modulation (AVIM) Therapy and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB), are currently undergoing pivotal clinical trials for their lead indications, each representing multi-billion-dollar annual global market opportunities. AVIM Therapy is a bioelectronic treatment for hypertension, the leading risk factor for death worldwide, and is designed to be delivered by a pacemaker and achieve immediate, substantial and sustained reductions in blood pressure in patients with hypertensive heart disease. The Company has a strategic collaboration with Medtronic, one of the largest medical device companies in the world and the global leader in cardiac pacing therapies, for the development and commercialization of AVIM Therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients. AVIM Therapy has FDA Breakthrough Device Designations for these patients, as well as an estimated 7.7 million total patients in the U.S. with uncontrolled hypertension despite medical therapy and increased cardiovascular risk. Virtue SAB is a highly differentiated, first-of-its-kind non-coated drug delivery angioplasty balloon system designed to deliver a large liquid dose of proprietary extended-release formulation of si